Literature DB >> 7379313

Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride.

P G Chiodini, A Liuzzi, G Verde, R Cozzi, F Silvestrini, M T Marsili, R Horowski, F Passerini, G Luccarelli, P G Borghi.   

Abstract

A 38-year-old amenorrhoeic woman suffering from a prolactin (PRL) secreting adenoma, which had suprasellar extension as shown by caroe agonist (lisuride). PRL levels were lowered and after 1 year of treatment CAT showed a marked reduction of the tumour size. After 2 years of treatment menstruation returned and CAT demonstrated a further reduction of the adenomatous tissue. This study supports the suggestion that dopamine agonists possess an anti-proliferative effect on tumoural lactotrophic cells of humans.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7379313     DOI: 10.1111/j.1365-2265.1980.tb03131.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Classical dopamine agonists.

Authors:  R Horowski; P-A Löschmann
Journal:  J Neural Transm (Vienna)       Date:  2019-02-25       Impact factor: 3.575

2.  Microprolactinomas: why requiem for surgery?

Authors:  A Liuzzi; G Oppizzi
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

3.  The management of prolactin-secreting pituitary tumors.

Authors:  S R George; G N Burrow
Journal:  J Endocrinol Invest       Date:  1981 Oct-Dec       Impact factor: 4.256

4.  Dopaminergic resistance in a case of invasive macroprolactinoma.

Authors:  D Schwarzstein; A García-Patterson; G Giménez; J Calaf; M Puig-Domingo; A Caixàs; X Matías-Guiu; S M Webb
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

5.  Effect of chronic bromocriptine administration on tumor size in patients with "nonsecreting" pituitary adenomas.

Authors:  G Verde; G Oppizzi; P G Chiodini; D Dallabonzana; G Luccarelli; A Liuzzi
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.